BCWM
ABBV icon

Ball & Co Wealth Management’s AbbVie ABBV Stock Holding History

Ball & Co Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$490K Buy
2,253
+16
+0.7% +$3.55K 0.41% 15
2025
Q4 		$511K Sell
2,237
-34
-1% -$7.75K 0.33% 22
2025
Q3 		$525K Buy
2,271
+18
+0.8% +$3.67K 0.35% 20
2025
Q2 		$418K Buy
2,253
+20
+0.9% +$3.72K 0.45% 14
2025
Q1 		$467K Buy
2,233
+19
+0.9% +$3.69K 0.5% 14
2024
Q4 		$393K Buy
+2,214
New +$407K 0.31% 14

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ball & Co Wealth Management's ABBV Position: Q1 2026 in Review

Ball & Co Wealth Management increased its AbbVie (ABBV) stake by 0.72% in Q1 2026, buying an estimated $3.55K and bringing the position to 2,253 shares worth $490K. The position accounts for 0.41% of the portfolio, ranked #15.

Ball & Co Wealth Management first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $525K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Ball & Co Wealth Management held 2,253 shares of AbbVie worth $490K as of Q1 2026.
  • Ball & Co Wealth Management bought 16 AbbVie shares in Q1 2026, an estimated $3.55K.
  • AbbVie made up 0.41% of Ball & Co Wealth Management's portfolio in Q1 2026, its #15 holding.
  • Ball & Co Wealth Management first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • Ball & Co Wealth Management's AbbVie position peaked at $525K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ball & Co Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.